Free hair analysis
Hair Library

Hair Library · Hair Loss

Alopecia Areata: Causes, Types, Treatment and Regrowth

How alopecia areata starts, which types exist, how the SALT score grades it, what steroids and JAK inhibitors can do, and why a hair transplant is rarely the answer.

Diagram: in alopecia areata immune cells gather around the bulb of a growing hair follicle; the follicle survives, so new hair can grow back, often white at first
39sources
36in PubMed
12min read

Written by Nazmi Güldeş, Certified Trichologist · Medically reviewed by Dr. Teuku Adifitrian, Sp.BP-RE (Dr. Tompi), Plastic, Reconstructive and Aesthetic Surgeon · Last reviewed 30 October 2026

Reading level

Alopecia areata is an autoimmune condition in which your immune system turns on your own hair follicles, usually leaving smooth, round bald patches that appear suddenly.[1][2] The follicles are not scarred, so hair can grow back, and in many people it does.[3] What no one can promise is when it will return, or whether new patches will follow.

1Quick answerThe short answer, in a few sentences

What Is Alopecia Areata?

Alopecia areata (AA) is an autoimmune disease in which immune cells gather around the roots of growing hair follicles, causing sudden, non-scarring hair loss, most often in round patches on the scalp.[3][1] Nearly 2% of people get it at some point in their lives.[3] Because the follicle survives, hair can regrow, though relapses are common.[4]

How common is it? Pooled international data put the prevalence at 2.1%, yet German data found 0.21% in 2020, and figures differ widely by region.[5] Sudden shedding all over the head has other causes, which our guide to reasons for hair loss walks through.

2Complete guideFrom the first patch to treatment and surgery

Signs, Types and Causes of Alopecia Areata

Early Signs and Symptoms

The usual first sign is a well-defined bald patch that appears abruptly, most often on the scalp.[1] In early, active patches, small "exclamation mark" hairs can sit at the edge.[2]

Signs to look for:

  • Round, smooth patches with no scarring[2]
  • Gaps in the eyebrows, eyelashes or beard[6]
  • Nail changes, found in about 30% of people with AA, mostly pitting (20%) and trachyonychia (8%)[7]
  • Itch or pain, which in a 400-patient cohort eased as the hair regrew[8]

Brows affected? Read whether eyebrows grow back.

Types of Alopecia Areata

Patchy AA on the scalp is the most common type.[3] The others differ in where, and how much, hair is lost:

  • Alopecia totalis: all scalp hair is lost[6]
  • Alopecia universalis: scalp, facial and body hair are all lost[6]
  • Ophiasis: a symmetric band of loss across the back and sides of the scalp[9], uncommon and slower to regrow than other types[10]
  • Alopecia areata incognita: sudden, diffuse thinning without clear patches, which resembles telogen effluvium and usually has a better outlook than other subtypes[11]
Four head profiles showing patchy alopecia areata, ophiasis, alopecia totalis and alopecia universalis
The main patterns of alopecia areata. Illustration: Turkey Hair Center.

What Causes Alopecia Areata?

The leading explanation is a collapse of the follicle's immune privilege, its usual shelter from immune attack, after which immune cells gather around the bulb of follicles in the growth phaseGlossaryAnagen is the growing phase of the hair cycle. For scalp hair it lasts 2 to 6 years according to a Deutsches Ärzteblatt review, and 2 to 7 years according to Cleveland Clinic.
Open in the glossary →.[3][1] Cytotoxic CD8+ T cells drive the damage, and genetic and drug studies point to the JAK/STAT signalling pathway.[1] Genes matter too: AA is a complex, polygenic disease.[3]

AA often travels with other immune conditions. A 2025 meta-analysis of 18 case-control studies found higher odds of vitiligo (odds ratio 6.61), lupus (3.28), atopic dermatitis (2.63) and autoimmune thyroiditis (1.57) in people with AA.[12] Our thyroid hair loss guide covers that link.

Can Stress Cause Alopecia Areata?

Many people tie their first patch to a hard time. When 100 patients were asked about the two years before onset, 82% reported at least one strainful event (unwanted, unexpected and out of their control), most often loss of health or separation. Yet the same authors note that earlier studies on life events and AA reached conflicting results.[13]

Alopecia Areata in Women, Men and Children

Women. Ophiasis, one of the harder types to treat, shows a female predominance.[10]

Men. AA can clear patches in the beard as well as on the scalp.[6]

Smooth, round patch of alopecia areata in the beard stubble under the jaw
Alopecia areata in the beard, under the chin. Photo: XxRoxetteXx, CC BY-SA 3.0, via Wikimedia Commons, cropped.

Children. In 104 patients followed for at least seven years, full or significant regrowth occurred in 74% of childhood-onset cases against 94% of adult-onset cases.[4] Treatment choices are narrower too: the German S3 guideline restricts its strongest systemic recommendations to adults.[14]

Diagnosis and Severity: Alopecia Areata vs Other Hair Loss

How Alopecia Areata Is Diagnosed

Most cases are diagnosed by looking at the hair loss itself.[3] Trichoscopy, a magnified look at the hair and scalp through a dermatoscope, adds detail.[15] A systematic review of 30 studies found yellow dots, short vellus hairsGlossaryVellus hair is the fine, short, pale hair that covers most of the body. It is under 30 micrometres wide and under 2 millimetres long.
Open in the glossary →, black dots (in up to 84%) and exclamation mark hairs, at rates that varied widely between studies.[16]

No single sign proves AA, so doctors look for several together.[16] A scalp biopsy is kept for complex or unusual cases.[2]

The SALT Score: How Severity Is Graded

Doctors grade scalp involvement with the Severity of Alopecia Tool (SALT), a score from 0 (no scalp hair loss) to 100 (complete scalp hair loss).[17] A score of 50 or more has long defined severe disease and the point at which systemic treatment is considered.[18] In treatment trials, success usually means SALT 20 or less: at least 80% of the scalp covered.[19] Newer scales also weigh eyebrow and eyelash loss, emotional burden and treatment response.[18]

Alopecia Areata vs Androgenetic Alopecia and Other Hair Loss

Several conditions share clinical features with AA.[16] This is how they usually differ:

ConditionHow it starts and looksClues that set it apart
Alopecia areataSudden, well-defined, non-scarring patches[1]Yellow dots, black dots, exclamation mark hairs[16]
Androgenetic alopeciaCan begin in the teens and progresses in a pattern[20]Hairs turn finer and shorter under DHT[21]
Telogen effluviumDiffuse, non-scarring shedding[22]Follows a stress such as childbirth or sudden weight loss[22]
TrichotillomaniaLoss from hair pulling[23]Broken hairs of different lengths, flame hairs, V-sign[23]
Tinea capitisCan look like AA[16]Comma and corkscrew hairs in a study of children[15]
Traction alopeciaLoss after tight buns, braids or weaves[24]Hair casts; can scar if pulling continues[24]

One small study in children saw black dots only in tinea capitis, while the 30-study review found them in up to 84% of people with AA.[15][16] For pattern hair lossGlossaryAndrogenetic alopecia, or pattern baldness, is the pattern hair loss behind most male and female thinning. It is primarily driven by genetic predisposition and sensitivity to androgen hormones.
Open in the glossary → and the hormone behind it, read our page on DHT and hair loss.

Alopecia Areata Treatment, Regrowth and Hair Transplants

No treatment cures alopecia areata or prevents it. The aim is to calm the disease while it is active.[25]

Patchy Hair Loss: Steroids First

For mild to moderate AA (SALT below 50), first-line treatment is a corticosteroid, applied to the skin or injected into the patch, often alongside topical or oral minoxidilGlossaryMinoxidil is an established medication for certain types of hair loss. It is a drug, not a hair oil, and the FDA-approved label says not to use it for sudden or patchy hair loss.
Open in the glossary →.[18] Because hair can regrow on its own, watching and waiting is reasonable in some cases.[18] How minoxidil itself works is explained in our minoxidil entry.

In a double-blind trial of 105 patients, triamcinolone injections at 2.5, 5 and 10 mg/mL all beat saline over 12 weeks. The strongest dose worked best but thinned the skin most, so the authors suggest starting at 2.5 mg/mL.[26]

Contact immunotherapy with diphenylcyclopropenone (DPCP) or squaric acid dibutyl ester is a preferred treatment for severe AA. Across 45 studies, 65.5% regrew some hair and 32.3% regrew it completely, but 49.0% relapsed without maintenance treatment.[27]

JAK Inhibitors for Severe Alopecia Areata

JAK inhibitors are taken by mouth and block the JAK/STAT pathway behind the immune attack.[1] Three have FDA approval for severe AA:

DrugFDA approval for AADose on the labelMain trial result (SALT 20 or less)
Baricitinib (Olumiant)Adults, 2022[19]2 mg once daily; 4 mg if response is not adequate or loss is near total[19]38.8% and 35.9% on 4 mg at week 36, against 6.2% and 3.3% on placebo[17]
Ritlecitinib (Litfulo)Age 12 and over, 2023[28]50 mg once daily[28]23% on 50 mg at week 24, against 2% on placebo[29]
Deuruxolitinib (Leqselvi)Adults, 2024[30]8 mg twice daily[30]29.6% on 8 mg at week 24, against 0.8% on placebo[31]

The effect lasts only while you take the drug. When one-year responders were switched to placebo, 80% lost the benefit by week 152, against 7% of those who stayed on baricitinib, and most regained it once they restarted.[32]

All three labels carry a boxed warning about serious infections, death, cancer, major cardiovascular events and blood clots, based partly on another JAK inhibitor in people with rheumatoid arthritis.[19][28][30] In the baricitinib trials, acne, raised creatine kinase and higher cholesterol were more common than on placebo.[17]

A 2026 safety review takes a calmer view: risks seen in older rheumatoid arthritis patients should not be applied directly to well-selected adults with AA.[33]

Clinical detail: why the trial numbers do not rank the drugs

The baricitinib trials measured their main result at week 36 in adults, the ritlecitinib trial at week 24 in patients aged 12 and over, and the deuruxolitinib trial at week 24 in adults aged 18 to 65.[17][29][31]

How Long Does Alopecia Areata Last?

Follow-up studies give a range:

Time pointWhat studies found
Year 131.8% of a 400-patient cohort had relapsed, at a median of 28 weeks[8]
Years 1 to 479% of relapses happened within the first four years[4]
Year 7 and laterFull or significant regrowth in 74% of childhood-onset, 94% of adult-onset and 100% of late-onset cases[4]
Years 15 to 2268.3% of patients with the mildest disease at their first visit were free of AA, while 36.1% of the whole group had totalis or universalis[34]

The two long studies differ because they followed different people: 63 of the 191 patients in one had severe disease at the start, which predicted the outcome[34], while 88.5% in the other had mild disease at their first episode.[4]

Regrowth Signs to Look For

On trichoscopy, upright regrowing hairs signal new growth.[16] The first new hairs are often white; this is usually temporary, but in some people the white hair stays.[35]

Can You Have a Hair Transplant With Alopecia Areata?

A hair transplant is generally not a treatment for active alopecia areata. The sources point to four reasons:

  • The follicles are still there. AA preserves the follicle, so hair in a patch can regrow without surgery.[3]
  • The disease comes back. Relapses affected 44% of adult-onset and 52% of childhood-onset patients in one long follow-up.[4]
  • Grafts are not protected. In one man with eyebrow AA, a transplant gave eight months free of the disease before it returned in the brow.[36]
  • Injury can set off new patches. In people with relapsing AA, plucking hairs for a trichogram test was followed by new patches within 1 to 7 days.[37]

The few successes come from stable disease. In a man whose eyebrow AA had resisted treatment and had been stable for 18 months, eyebrow grafts taken by FUE reached 80% regrowth at two years. Even so, the authors call surgery for AA controversial.[38] Both cases involved an eyebrow transplant.[38][36]

Frequently Asked Questions

Is alopecia areata an autoimmune disease?
Yes. Cytotoxic CD8+ T cells attack the follicle after its immune privilege collapses.[1]
Can alopecia areata be cured?
Not yet. No treatment is curative or preventive.[25] Even after a year of good regrowth on baricitinib, most people who stopped lost it.[32]
Does hair grow back after alopecia areata?
Often, because the follicle is preserved.[3] In one study with at least seven years of follow-up, 94% of adult-onset patients had full or significant regrowth.[4]
Is alopecia areata genetic?
Partly. In a meta-analysis of 67 studies with 24,226 patients, 17.6% had a family history of AA, yet only 3.22% of their first-degree relatives were affected.[39]
Is alopecia areata contagious?
It is an autoimmune disease, not an infection: the damage comes from the person's own T cells.[1] Tinea capitis can look similar, and trichoscopy helps tell the two apart.[15]
Does alopecia areata spread?
It can. In a 15 to 22 year follow-up, severe patterns tended to get worse over time.[34] Young onset, extensive loss, ophiasis, nail changes, a family history and other autoimmune diseases point to a harder course.[2]
Does alopecia areata come and go?
Often. In a cohort of 400 patients, 31.8% relapsed within a year, at a median of 28 weeks, and those with earlier episodes were at higher risk.[8]

Treatment, Waiting or Surgery: What Suits You?

Alopecia areata is a medical condition first. If your patches are new or spreading, see a dermatologist: treatments from steroid injections to JAK inhibitors now have trial evidence.[18][17] The German S3 guideline also recommends telling everyone with AA about hair replacement and cosmetic options.[14] A transplant suits only a small group with long-stable disease, and even then AA can return.[38][36]

Not sure whether your loss is alopecia areata or pattern hair loss that a transplant could treat? Send three photos for a free hair analysis, and the medical team will tell you which it looks like and whether to see a dermatologist first. You can also message us on WhatsApp.

About the Author

Written by: Nazmi Güldeş, Certified Trichologist. Nazmi Güldeş focuses on patient education around androgenetic alopecia, evaluating miniaturization through dermoscopy, and assessing candidates for medical treatments and hair transplants.

Editorial Policy & Trust

This entry was drafted with the help of AI writing tools and edited by our team, then medically reviewed by Dr. Teuku Adifitrian, Sp.BP-RE (Dr. Tompi) on 30 October 2026. AI is never used as a source: every study cited here was checked against PubMed on 30 October 2026, and each claim sits next to the study that supports it. Read how we work in our editorial policy.

3 questions

Test yourself

Check what you remember from this entry. Each answer links back to the section that explains it.

  1. Which SALT score usually counts as success in alopecia areata treatment trials?
  2. What happened when one-year baricitinib responders were switched to placebo?
  3. Why is a hair transplant generally not used for active alopecia areata?
3Scientific evidenceStudy types, references and how to cite this entry
39sources

Evidence behind this entry: 36 publications indexed in PubMed (2005 to 2026): 11 reviews, 7 clinical studies, 5 guidelines, 5 randomized trials, 4 case reports and 4 systematic reviews. Plus the FDA prescribing information for Olumiant (baricitinib), Litfulo (ritlecitinib) and Leqselvi (deuruxolitinib). 12 sources have free full text. 1 article has a published correction, shown in the references.

  • Randomized trialpeople assigned to treatments by chance
  • Reviewsummarises many studies
  • Clinical studya study in people without random groups
  • Guideline or labela professional body, or the official drug label

Every source checked against PubMed on 30 October 2026, including corrections and retractions. See the newest studies on PubMed →

References

  1. Maas D, Spindler AJ, Zappi I, et al. Alopecia Areata: Advances in Clinical Evaluation and Pathogenesis. Journal of the American Academy of Dermatology. 2026.ReviewPubMedDOI
  2. Spano F, Donovan JC. Alopecia areata: Part 1: pathogenesis, diagnosis, and prognosis. Canadian Family Physician Medecin de Famille Canadien. 2015;61(9):751-755.ReviewPubMedFree full text
  3. Pratt CH, King LE Jr, Messenger AG, et al. Alopecia areata. Nature Reviews Disease Primers. 2017;3:17011.ReviewPubMedDOIFree full text
  4. Lyakhovitsky A, Aronovich A, Gilboa S, et al. Alopecia areata: a long-term follow-up study of 104 patients. Journal of the European Academy of Dermatology and Venereology. 2019;33(8):1602-1609.Clinical studyPubMedDOI
  5. Blume-Peytavi U, Constantinou A, Tomova-Simitchieva T, et al. S3 guideline diagnostics and therapy of alopecia areata - Part 1: Diagnostics and epidemiology. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology. 2026;24(7):e1000-e1015.GuidelinePubMedDOIFree full text
  6. Harries MJ, Ahmed A, Ascott A, et al. British Association of Dermatologists living guideline for managing people with alopecia areata 2025. The British Journal of Dermatology. 2026;194(2):e56-e73.GuidelinePubMedDOI
  7. Chelidze K, Lipner SR. Nail changes in alopecia areata: an update and review. International Journal of Dermatology. 2018;57(7):776-783.ReviewPubMedDOI
  8. Wenjie Y, Yue W, Mengjiao W, et al. Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study. Frontiers in Medicine. 2025;12:1695618.Clinical studyPubMedDOIFree full text
  9. Asad U, Wallis D, Tarbox M. Ophiasis alopecia areata treated with microneedling. Proceedings (Baylor University Medical Center). 2020;33(3):413-414.Case reportPubMedDOIFree full text
  10. Li F, Zhang W, Wang C, et al. Clinical characteristics, subtype classification, and prognostic factors of ophiasis: A retrospective study of 150 patients with therapeutic implications. Journal of the American Academy of Dermatology. 2026;95(2):400-408.Clinical studyPubMedDOI
  11. Rodríguez-Tamez G, Maskan-Bermudez N, Tosti A. Alopecia Areata Incognita: Current Evidence. Dermatology and Therapy. 2025;15(3):635-645.ReviewPubMedDOIFree full text
  12. Krajewski PK, Jastrząb B, Szepietowski JC, et al. Immune-Mediated Disorders in Patients With Alopecia Areata: Systematic Review and Meta-Analysis. International Journal of Dermatology. 2025;64(11):2029-2037.Systematic reviewPubMedDOI
  13. Fhager J, Örmon K, Svensson Å, et al. Life Events Preceding Alopecia Areata Onset-a Descriptive Retrospective Cohort Study Focusing on Strain. Clinical, Cosmetic and Investigational Dermatology. 2026;19:567911.Clinical studyPubMedDOIFree full text
  14. Blume-Peytavi U, Constantinou A, Tomova-Simitchieva T, et al. S3 guideline diagnostics and therapy in alopecia areata - Part 2: Therapy, psychosocial and cosmetic support. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology. 2026;24(8):e1155-e1177.GuidelinePubMedDOIFree full text
  15. Ekiz O, Sen BB, Rifaioğlu EN, et al. Trichoscopy in paediatric patients with tinea capitis: a useful method to differentiate from alopecia areata. Journal of the European Academy of Dermatology and Venereology. 2014;28(9):1255-1258.Clinical studyPubMedDOI
  16. Waśkiel A, Rakowska A, Sikora M, et al. Trichoscopy of alopecia areata: An update. The Journal of Dermatology. 2018;45(6):692-700.Systematic reviewPubMedDOI
  17. King B, Ohyama M, Kwon O, et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. The New England Journal of Medicine. 2022;386(18):1687-1699.Randomized trialPubMedDOI
  18. Spindler A, Maas D, Zappi I, et al. Alopecia areata: Emerging therapies and up-to-date management strategies. Journal of the American Academy of Dermatology. 2026.ReviewPubMedDOI
  19. U.S. Food and Drug Administration. OLUMIANT (baricitinib) tablets, for oral use: prescribing information. Revised June 2022.Drug labelSource page
  20. Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. Journal of the European Academy of Dermatology and Venereology. 2018;32(1):11-22.GuidelinePubMedDOI
  21. Alessandrini A, Starace M, D'Ovidio R, et al. Androgenetic alopecia in women and men: Italian guidelines adapted from European Dermatology Forum/European Academy of Dermatology and Venereology guidelines. Giornale Italiano Di Dermatologia E Venereologia. 2020;155(5):622-631.GuidelinePubMedDOI
  22. Chien Yin GO, Siong-See JL, Wang ECE. Telogen Effluvium - a review of the science and current obstacles. Journal of Dermatological Science. 2021;101(3):156-163.ReviewPubMedDOI
  23. Mani S, Raut A, Neema S, et al. Trichoscopy in Alopecia Areata and Trichotillomania in Skin of Colour: A Comparative Study. Indian Journal of Dermatology. 2023;68(1):78-84.Clinical studyPubMedDOIFree full text
  24. Billero V, Miteva M. Traction alopecia: the root of the problem. Clinical, Cosmetic and Investigational Dermatology. 2018;11:149-159.ReviewPubMedDOIFree full text
  25. Alkhalifah A, Alsantali A, Wang E, et al. Alopecia areata update: part II. Treatment. Journal of the American Academy of Dermatology. 2010;62(2):191-202, quiz 203-4.ReviewPubMedDOI
  26. Rajan M B, Bhardwaj A, Singh S, et al. Identification of novel step-up regimen of intralesional triamcinolone acetonide in scalp alopecia areata based on a double-blind randomized controlled trial. Dermatologic Therapy. 2021;34(1):e14555.Randomized trialPubMedDOI
  27. Lee S, Kim BJ, Lee YB, et al. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis. JAMA Dermatology. 2018;154(10):1145-1151.Systematic reviewPubMedDOIFree full text
  28. U.S. Food and Drug Administration. LITFULO (ritlecitinib) capsules, for oral use: prescribing information. Revised June 2023.Drug labelSource page
  29. King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet (London, England). 2023;401(10387):1518-1529.Randomized trialPubMedDOIA correction to this article was published: Lancet. 2023 Jun 10;401(10392):1928. doi: 10.1016/S0140-6736(23)01078-4. (PubMed).
  30. U.S. Food and Drug Administration. LEQSELVI (deuruxolitinib) tablets, for oral use: prescribing information. Revised July 2024.Drug labelSource page
  31. King B, Senna MM, Mesinkovska NA, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). Journal of the American Academy of Dermatology. 2024;91(5):880-888.Randomized trialPubMedDOI
  32. King B, Ko J, Kwon O, et al. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial. JAMA Dermatology. 2024;160(10):1075-1081.Randomized trialPubMedDOIFree full text
  33. Thanomkitti K, Spagnolini S, Tosti A. A safety review of JAK inhibitors for managing alopecia areata. Expert Opinion on Drug Safety. 2026.ReviewPubMedDOI
  34. Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. Journal of the American Academy of Dermatology. 2006;55(3):438-441.Clinical studyPubMedDOI
  35. Asz-Sigall D, Ortega-Springall MF, Smith-Pliego M, et al. White hair in alopecia areata: Clinical forms and proposed physiopathologic mechanisms. Journal of the American Academy of Dermatology. 2023;89(4):758-763.ReviewPubMedDOI
  36. Barankin B, Taher M, Wasel N. Successful hair transplant of eyebrow alopecia areata. Journal of Cutaneous Medicine and Surgery. 2005;9(4):162-164.Case reportPubMedDOI
  37. D'Ovidio R. Koebner phenomenon in alopecia areata: rapid appearance after trichogram. Implications for the pathogenesis and therapy. Giornale Italiano Di Dermatologia E Venereologia. 2013;148(2):225-229.Case reportPubMed
  38. Civaş E, Aksoy B, Aksoy HM, et al. Hair transplantation for therapy-resistant alopecia areata of the eyebrows: is it the right choice?. The Journal of Dermatology. 2010;37(9):823-826.Case reportPubMedDOI
  39. Huang Y, Jee E, Kim M, et al. Familial patterns of alopecia areata: A systematic review and meta-analysis. Journal of Autoimmunity. 2025;151:103378.Systematic reviewPubMedDOI
Written byNazmi Güldeş, Certified Trichologist
Sources39 references
Medically reviewed byDr. Teuku Adifitrian, Sp.BP-RE (Dr. Tompi), Plastic, Reconstructive and Aesthetic Surgeon
Last reviewed30 October 2026
Last updated30 October 2026
Cite this entry
Güldeş, N. (2026, October 30). Alopecia areata: Causes, types, treatment and regrowth. Turkey Hair Center Hair Library. https://turkeyhaircenter.com/alopecia-areata/
Spotted an error? See our corrections policy · How we use sources
Next in Hair LossThyroid Hair LossHow thyroid problems affect hair, the link with alopecia areata and which tests to ask for.Read next →Reading path · step 3 of 5Telogen EffluviumDiffuse shedding that follows a stress on the body, and how it differs from alopecia areata.Continue the path →

Keep exploring Hair Loss

Do Eyebrows Grow Back?

How long regrowth takes after plucking, chemo, alopecia areata or thyroid loss, and the signs that loss is permanent.

Read Do Eyebrows Grow Back? Thyroid Hair Loss

How hypo and hyperthyroidism and Hashimoto's affect hair, when it grows back and which tests to ask for.

Read Thyroid Hair Loss Shock Loss After Hair Transplant

The temporary shedding that usually starts 2 to 4 weeks after a transplant, and how to tell it apart from graft failure.

Read Shock Loss After Hair Transplant Eyebrow Transplant

How single hairs are moved to the brows, how many grafts are used, recovery week by week and what the price depends on.

Read Eyebrow Transplant

Ask the Medical Team
About Your Case

Send three photos: front, top and sides. You get a technique recommendation, a graft range and a straight answer about what is achievable, before anyone talks about price.

Please tell us your name.
We need a number the medical team can reach you on.
That email address does not look right.
Country * Please choose your country.
Which area concerns you most?
Treatment you are asking about
0 / 500

Your details go straight to the patient coordination team and are stored confidentially. We never share them with third parties.

We typically reply within minutes, 24/7.

Your details are with the team

A patient coordinator will get back to you shortly. If you would like to send your photos now, WhatsApp is the fastest way to do it.

See the results timeline
Turkey Hair Center patient coordinator Real People
Real Support
  • Send your photos on WhatsApp

    Front, top and both sides, reviewed by the medical team.

  • Call us directly

    Speak to a patient coordinator on the phone.

    +90 545 249 91 04
  • 24/7 patient support

    We respond quickly, day or night, in your language.

    Multilingual team, no obligation
Data protectedKVKK and GDPR compliant, 100% confidential

Explore the Hair Library

88 entries, 46 glossary terms and every source linked to PubMed. Pick a topic and keep reading.

Hair Loss18 entriesHair Loss Treatments11 entriesHair Biology8 entriesGlossary46 terms
Authorized Health Tourism Intermediary

Turkey Hair Center is the hair-restoration brand of Healthy Way Tourism, an authorized international health-tourism intermediary.
All medical procedures are performed by licensed medical professionals at authorized healthcare facilities in Turkiye, in accordance with the regulations of the Ministry of Health.

About our authorisation